AUTL News and Press, Autolus Therapeutics plc From 03/09/22

Autolus Therapeutics (NASDAQ:AUTL) is scheduled to announce Q4 earnings results on Thursday, Mar. 10, before market open. The consensus EPS estimate is -$0.36 and the consensus revenue estimate is $5.85M. Over the last 2 years, AUTL has beaten EPS estimates 63% of the time and has beaten reve...

AFCG, AG, AMTX, ATY, AUTL, BBW, BTAI, BZUN, CCLP, DCBO, DESP, DLTH, EMAN, ENG, ESTE, EVGN, EXK, FCEL, GNCA, GWRS, JD, KNOP, LAZY, LIZI, ML, NEON, OTCQX:QTRHF, SELB, SHIP, TEO, THRY, TXMD, UP, VITL, XERS For Seeking Alpha's full earnings season calendar, click here. For further details see: ...

- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module 1 - Method for expressing stable low levels of a toxic gene - technology deployed in Autolus’ approach for the treatmen...

LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operati...

- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T ce...

- obe-cel has the potential to transform outcomes for adult ALL patients - Phase 2 FELIX study data expected in 2022 LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation progra...

LONDON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that they are scheduled to deliver a corporate presentation at the following virtual con...

The following slide deck was published by Autolus Therapeutics plc in conjunction with this event. For further details see: Autolus Therapeutics (AUTL) Presents At 63rd Annual Meeting of ASH - Slideshow

- Obe-cel shows sustained durability of response with morphological EFS of 46% at 24 months in the ALLCAR19 study - Obe-cel response and safety data from the Phase 1b portion of the FELIX study consistent with the Phase 1 ALLCAR19 study - Obe-cel achieves a metaboli...

LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it will hold a conference call to discuss the data being presented at the 63rd Amer...